Your muscles clear most of the glucose insulin sends into the bloodstream, bank the amino acids you fall back on in illness, and secrete hundreds of signalling molecules that talk to fat, liver, bone, and brain. The case for treating muscle as an organ is strong. So are the limits of the slogan. Here is both.
Ask most people what muscle is for and they will say movement, or appearance. Both answers undersell the tissue by a wide margin. Skeletal muscle is roughly 40% of your body mass, it is where most of a meal’s glucose ends up, it is the protein reserve your body raids when you are sick, and it is a secretory organ in its own right. Medicine has been slow to treat it that way: we measure blood pressure, cholesterol, and blood sugar obsessively, and muscle almost never. This piece covers what muscle does metabolically, what happens as it disappears with age, what rebuilds it, and where the “muscle is medicine” slogan runs ahead of the evidence.
An organ, not an accessory

Calling muscle an endocrine organ is no longer a metaphor. Reviews in the field now describe skeletal muscle as essential for movement, breathing, and heat production, and as a tissue that secretes signalling molecules and handles most insulin-driven glucose disposal.[1] Bente Pedersen’s group at the University of Copenhagen formalized the idea: muscle fibres produce and release peptides, myokines, that act on the muscle itself, on neighbouring tissue, and through the bloodstream on distant organs. By 2012 they could write that “the muscle secretome consists of several hundred secreted peptides” and that muscles “communicate with other organs, such as adipose tissue, liver, pancreas, bones and brain.”[2]
Muscle’s jobs beyond movement:
- Glucose sink. Muscle is the main site of insulin-stimulated glucose uptake and the predominant site of glycogen storage. It is the body’s largest single destination for blood sugar after a meal.
- Amino-acid reservoir. Muscle protein is the bank the body draws on during fasting, illness, trauma, or sepsis, releasing amino acids, especially alanine and glutamine, for the liver to turn into glucose and for immune cells and wounds to build with. In a classic 1976 study, 60 hours of fasting raised muscle’s release of glycogenic amino acids by about 69% on average.[3] Low muscle means low reserve: the same illness or week of bed rest costs a person with little muscle proportionally more function.
- Heat and energy. Muscle is essential for thermogenesis and is a major consumer of glucose and contributor to whole-body energy metabolism.[1]
- Endocrine signalling. The myokines, covered in their own section below.
The glucose sink, and the condition attached to the famous 80%
The number you will see quoted everywhere is that muscle handles about 80% of glucose disposal. It is a real number from real physiology, with a condition attached that usually gets dropped. It comes from the euglycemic insulin clamp, the laboratory technique in which insulin is infused at a high, steady rate. Under those insulin-stimulated conditions, Ralph DeFronzo’s group established that roughly 80% of glucose uptake occurs in skeletal muscle, and about three-quarters of it is stored rather than burned. It is converted to glycogen, and impaired glycogen synthesis is one of the earliest defects in type 2 diabetes.[4]
Now the contrast the slogan leaves out. In the fasting, postabsorptive state, which covers most of your day, the majority of glucose uptake, about 70 to 75%, happens in tissues that do not need insulin at all: the brain, red blood cells, and the gut and liver region. Only about a quarter goes to insulin-sensitive tissues like muscle.[4] Toggle between the two states to see how different the picture is:
One tissue, two very different states
Where glucose uptake happens
Source: DeFronzo RA & Tripathy D. Diabetes Care. 2009;32(Suppl 2):S157, S163. Shares are of total glucose uptake in each state, not of everything you eat.
The mechanism explains a lot of the rest. Insulin docks at its receptor on the muscle cell, a signalling chain (IRS-1 → PI3-kinase → Akt → AS160) moves GLUT4 transporters to the cell surface, and glucose flows in to be burned or stored as glycogen. Insulin resistance in muscle is a failure of that chain: less transport, less storage.[4] And there is a second door: muscle contraction itself stimulates glucose uptake through an insulin-independent pathway. That is why a walk after a meal lowers blood glucose even in people whose insulin signalling is impaired. The contracting muscle pulls glucose in whether insulin’s key works or not.[1]
Where type 2 diabetes begins
DeFronzo’s central claim, and it has held up well, is that skeletal muscle insulin resistance is “the initiating or primary defect” in type 2 diabetes, detectable decades before blood sugar rises. The cleanest evidence: lean, normal-glucose-tolerant young adults whose both parents have type 2 diabetes already show moderate-to-severe muscle insulin resistance, with glucose uptake reduced 33 to 43% at clamp insulin levels, explained entirely by reduced glycogen synthesis, while their livers suppress glucose normally. In lean people who already have diabetes, insulin-stimulated leg-muscle glucose uptake is reduced by about half.[4]
Keep the nuance in mind. It limits everything that follows: “primary” in this literature means earliest detectable, not “the only cause.” Liver, fat tissue, gut, and pancreatic defects all contribute, and DeFronzo is explicit that beta-cell failure is the sine qua non: without it, diabetes never becomes overt, however insulin resistant the muscle. Muscle is where the disease starts. It is not the whole disease.
More muscle, better insulin sensitivity, mostly association
The population evidence linking muscle to metabolic health is large and consistent. In NHANES III (13,644 US adults), Preethi Srikanthan and Arun Karlamangla measured skeletal muscle mass relative to body weight and found that, after adjusting for age, ethnicity, sex, and both general and central obesity, each 10% increase in relative muscle mass was associated with an 11% relative reduction in insulin resistance (HOMA-IR) and a 12% relative reduction in the prevalence of prediabetes or overt diabetes.[5] A 2025 systematic review of 25 prospective cohort studies, 278,475 participants in the muscle mass analyses and 400,181 in the strength analyses, found that muscle mass relative to body weight, and grip strength relative to BMI, were consistently and inversely associated with developing type 2 diabetes.[6]
The worst phenotype is the combination: sarcopenic obesity, excess fat with low muscle, which a large UK Biobank analysis reported as carrying the highest diabetes risk of any body-composition group, above obesity alone and above low muscle alone. That figure currently rests on a news summary of the paper rather than the paper itself, so treat the exact multiple as provisional.[7] A 16-year Korean cohort presented at ENDO 2024 points the same way. Diabetes risk rose as weight-adjusted muscle mass fell. But that is a conference abstract, not yet a full peer-reviewed paper.[8]
Two honest limits on this section. First, the flagship NHANES analysis is cross sectional: it photographs one moment and cannot show that gaining muscle causes the improvement; its muscle mass was also estimated by bioelectrical impedance, an imprecise method. Second, and this matters for how you act on it, the intervention evidence does not isolate kilograms of muscle. Resistance training improves insulin sensitivity acutely and chronically through contraction-mediated glucose uptake, more GLUT4, and mitochondrial and vascular adaptations, including in people who gain little visible mass. Attribute the metabolic benefit to training and muscle quality, not to the scale of your lean mass alone.
Muscle talks: the myokines
If the glucose story is muscle as a sink, the myokine story is muscle as a broadcaster. A 2026 review in the Archives of Pharmacal Research sorts the field by evidence strength: Tier 1 myokines have demonstrable human interventional or causal evidence; Tier 2 have defined targets but largely correlative human data; Tier 3 is exploratory.[9] Only four signals make Tier 1: IL-6, the myostatin pathway, FGF21, and apelin. Tap through the five names you will meet most often:
Explore the signals
Five myokines, honestly graded
Tiering: “Exercise-induced myokines in metabolic regulation.” Arch Pharm Res. 2026. Primary sources as cited per molecule.
What this evidence supports: contracting muscle genuinely is a secretory organ, exercise changes the circulating levels of hundreds of proteins, and IL-6 anchors the concept in humans. What it does not support: a blood test that prescribes your training, a single molecule that explains exercise, or an “exercise pill.” No myokine mimetic is approved for metabolic disease or sarcopenia. The myokine field is young, and much of it is still animal work. The irisin story above is the cautionary tale the field itself tells.
Aging: strength leaves three times faster than mass
The word is sarcopenia, from the Greek sarx (flesh) and penia (loss). Irwin Rosenberg proposed it in 1989. The current European consensus (EWGSOP2, 2019) defines it as a muscle disease and made low strength, not low mass, the primary characteristic: low muscle quantity or quality confirms the diagnosis, and poor physical performance marks it severe.[10] The cutoffs the consensus uses:
The diagnostic lines · EWGSOP2, 2019
When low becomes a diagnosis
Source: Cruz-Jentoft AJ et al. Age Aging. 2019;48(1):16 to 31. Sarcopenia has been a coded disease (ICD-10-CM M62.84) since 2016.
How common is it? A 2022 meta-analysis of 151 studies and 692,056 people found prevalence of 10 to 27% depending on the definition used. Across the wider literature, reported prevalence runs from under 1% to over 85% purely because definitions differ. Anyone who gives you a single prevalence figure without naming the definition is selling something.[11]
The key aging finding is a ratio. In the Health, Aging and Body Composition Study, 1,880 older adults followed for three years, leg strength fell at roughly 3% per year while leg lean mass fell at roughly 1% per year. Strength drains about three times faster than size, and the authors’ conclusion deserves emphasis: “maintaining or gaining muscle mass does not prevent aging-associated declines in muscle strength.” What leaks away is muscle quality: neural drive, fiber type, fat infiltrating the muscle, not just quantity.[12]
Health ABC, annualized change
The gap that defines aging muscle
Source: Goodpaster BH et al. J Gerontol A Biol Sci Med Sci. 2006;61:1059 to 1064 (Health ABC).
That is why strength, measured cheaply, predicts so much. In the same Health ABC cohort, Anne Newman and colleagues found that quadriceps strength predicted mortality, while muscle size by CT or DXA “was not strongly related to mortality” in the same people. Grip strength gave similar risk estimates to the quadriceps measurement.[13] The largest test of that idea is the PURE study: 139,691 adults aged 35 to 70 in 17 countries, followed a median of four years. Each 5 kg lower grip strength was associated with a 16% higher risk of death (HR 1.16, 95% CI 1.13 to 1.20), with similar figures for cardiovascular and non-cardiovascular death, and grip strength was “a stronger predictor of all-cause and cardiovascular mortality than systolic blood pressure.”[14] The outcomes data line up behind it: a 2026 meta-analysis of 39 cohort studies in community-dwelling older adults found sarcopenia associated with roughly 79% higher odds of death (OR 1.79) and 90% higher odds of functional decline (OR 1.90).[15]
Two cautions on those striking numbers. First, PURE itself contains a useful negative: grip strength showed no significant association with developing diabetes, hospital admission for pneumonia or COPD, injury from falls, or fractures in that analysis. Grip does not predict everything. Second, all of this is observational. Weaker people die sooner, but illness also makes people weak, and the PURE authors say so themselves: research is still needed “to test whether improvement in strength reduces mortality.” Prediction is not yet proof that building strength buys back the risk.
What actually builds and preserves it
The guideline floor is the World Health Organization’s: on top of 150 to 300 minutes a week of moderate aerobic activity, adults should do muscle-strengthening activities involving all major muscle groups on two or more days a week; older adults add balance and functional training on three or more days.[16] Cohort data suggest the bar for benefit is lower than most people fear: a 2022 meta-analysis of 16 prospective studies found muscle-strengthening activity associated with 10 to 17% lower risk of death, cardiovascular disease, cancer, and diabetes. It followed a J-shaped dose response, with maximum benefit around 30 to 60 minutes a week, and the effect of much higher volumes is unclear.[17] Observational and mostly self reported, but a useful corrective to the idea that the dose must be heroic.
And it works late. A 2026 meta-analysis of 25 randomized trials in 1,302 older adults with sarcopenia found resistance training improved strength (effect size 0.71), grip (0.55), and walking ability (0.41), while lean mass moved far less (0.22). A second meta-analysis in frail and pre-frail adults over 65 found the same pattern: lower-limb strength effect 0.93, muscle mass 0.29.[18][19] The classic proof of principle is older still: in 1994, Fiatarone and colleagues put nursing-home residents in their nineties on high-intensity progressive resistance training and improved their strength and function. The trial is cited for showing it is possible and effective in the very old, which is the point that matters.[20] The practical prescription the evidence supports: two to three full-body sessions a week, multi-joint movements for the major muscle groups, progressive load, roughly 2 to 4 sets of 6 to 15 reps at 60 to 80% of one-rep max, leaving a few reps in reserve.
Protein: the RDA is a floor, not a target
The 0.8 g/kg/day RDA is the minimum to avoid deficiency, not an optimum. Older muscle is “anabolically resistant” and needs more protein per meal to trigger building. The PROT-AGE study group’s evidence-based targets, the sports-nutrition position stand, and the largest protein meta-analysis give a consistent ladder:
Grams per kilogram of body weight, per day
Protein targets
| Who | Target | Source |
|---|---|---|
| General adult, the RDA minimum | 0.8 g/kg | Institute of Medicine |
| Healthy older adult, over 65 | 1.0 to 1.2 g/kg | PROT-AGE, 2013 |
| Older adult who exercises | ≥1.2 g/kg | PROT-AGE, 2013 |
| Older adult with acute or chronic illness | 1.2 to 1.5 g/kg | PROT-AGE, 2013 |
| Exercising adult building or keeping muscle | 1.4 to 2.0 g/kg | ISSN position stand, 2017 |
| Plateau for training gains | ~1.6 g/kg | Morton et al., 2018 |
Bauer J et al. J Am Med Dir Assoc. 2013;14(8):542 to 559 (PROT-AGE); Morton RW et al. Br J Sports Med. 2018;52(6):376 to 384. Exception: severe kidney disease (eGFR <30, not on dialysis). Protein is restricted and individualized with a clinician.
Do the arithmetic
Your daily protein target
Enter your body weight and pick the row that describes you. This uses only the published targets above. It is a starting point for a conversation, not a prescription.
Two cautions before you chase a number. In Morton and colleagues’ meta-analysis of 49 trials, protein supplementation on top of training added, on average, 0.30 kg of fat-free mass. Real, but small; intakes above roughly 1.6 g/kg/day did not add further gains, and the effect shrank with age. Protein helps; training is the main driver, and 1.6 is a population plateau, not a personal minimum.[21] Spread matters too: PROT-AGE suggests roughly 25 to 30 g of protein per meal for older adults rather than the usual pattern of almost none at breakfast and a mountain at dinner. One safety point. These higher targets appear safe with normal kidney function in the expert reviews. People with kidney disease should set their target with their clinician, not with an article.
Testosterone: a treatment for a diagnosis, not a tonic
Because I prescribe hormone therapy, I get asked whether testosterone is the shortcut to keeping muscle. It is not, and the Endocrine Society’s 2026 statement is blunt about the boundary: replacement is for men with symptoms plus consistently low, accurately measured testosterone, at least two early-morning fasting tests, with a common threshold near 300 ng/dL, and not as population screening or an anti-aging prescription. In the trials, its benefits for muscle strength and physical function are described as potential and modest, alongside a consistent, modest benefit for libido.[22] The safety ledger from TRAVERSE, over 5,200 men treated for one to four years, found no meaningful increase in heart attack or stroke, but an approximately 50% relative increase in pulmonary embolism and an increased incidence of fractures, with long-term safety, including prostate cancer, still unestablished. The European menopause society’s position adds that testosterone should not be used routinely in older men to improve exercise capacity or cognition.[23] For overweight men whose low testosterone has no other cause, weight loss is typically first line. Testosterone treats diagnosed hypogonadism. Training and protein treat aging muscle.
Where the slogan overreaches
“Muscle is medicine” is a framing I use in my own book, and like any framing, it can be stretched past what the evidence holds. Here are the versions you will hear, with the verdicts the literature supports:
The bottom line
- Muscle is the main insulin-stimulated glucose sink, about 80% of disposal under clamp conditions, and a genuine secretory organ, with IL-6 anchoring a secretome of hundreds of peptides.
- Relative muscle mass, and especially strength, are consistently associated with better insulin sensitivity, less type 2 diabetes, less disability, and lower mortality. Fat mass is the key confounder, and causation is not yet proven by a mortality trial.
- Strength falls about three times faster than mass with age, and strength and function predict outcomes better than size. The goal is strong, functional muscle, not just a bigger DXA number.
- The prescription that works: progressive resistance training at least two days a week, plus protein at 1.0 to 1.2 g/kg/day for healthy older adults (up to about 1.6 g/kg/day for those training hard). It works at 85 and beyond.
- Testosterone is for diagnosed hypogonadism only. Myokine drugs for healthy aging do not exist. Muscle is a lever, powerful, modifiable, and undermeasured, alongside aerobic exercise, weight, sleep, and actual medical treatment.
What we still don’t know
- Whether building strength extends life. No trial has randomized adults to strength training with mortality as the endpoint; every mortality link above is observational, with confounding and reverse causation impossible to exclude.
- The exact sarcopenic-obesity risk. The UK Biobank finding (highest diabetes risk of any body-composition group) was read for this article via a news summary; the primary Diabetes Care paper’s adjusted hazard ratios and definitions have not been verified here.
- The Korean 16-year cohort linking falling muscle mass to incident diabetes exists so far as a 2024 conference abstract; the full peer-reviewed paper has not been verified.
- Whether irisin does anything in humans. Its detection in human blood by mass spectrometry is reported in secondary sources; no human trial of irisin exists, and its fat-browning effect at real-world concentrations is unproven.
- Per-meal protein dosing. The precise per-meal figures sometimes quoted for older adults (about 0.40 g/kg per meal, 2.5 to 3 g leucine) come from secondary summaries in this research, not verified primary papers, which is why this article uses PROT-AGE’s 25 to 30 g per meal instead.
- Vitamin D, growth hormone, and sleep for muscle. All plausibly matter; no verified effect size or guideline for “optimizing” them for muscle was established in this research, so this article makes no claim for them.
Sources
- Feraco A, et al. Exploring the role of skeletal muscle in insulin resistance: lessons from cultured cells to animal models. Int J Mol Sci. 2021;22:9327. pubmed.ncbi.nlm.nih.gov/34502235
- Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol. 2012;8:457 to 465. ncbi.nlm.nih.gov/pubmed/22473333
- Pozefsky T, et al. Effects of brief starvation on muscle amino acid metabolism in nonobese man. J Clin Invest. 1976;57:444 to 449. doi:10.1172/JCI108295.
- DeFronzo RA, Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care. 2009;32(Suppl 2):S157, S163. pmc.ncbi.nlm.nih.gov/articles/PMC2811436
- Srikanthan P, Karlamangla AS. Relative muscle mass is inversely associated with insulin resistance and prediabetes: findings from NHANES III. J Clin Endocrinol Metab. 2011;96(9):2898 to 2903. pubmed.ncbi.nlm.nih.gov/21778224
- Putranata H, Hengky A, Hartoko B. Unraveling the role of muscle mass and strength in predicting type 2 diabetes risk: a systematic review. Acta Diabetol. 2025;62(2):157 to 176. pubmed.ncbi.nlm.nih.gov/39760787
- Guan Z, et al. Sarcopenic obesity and risk of incident type 2 diabetes: a prospective cohort study and landmark analysis from the UK Biobank. Diabetes Care. 2026 (doi reported: 10.2337/dc26-0797). As summarised in: medicalxpress.com, news summary; primary paper not opened for this article.
- Mun H, et al. Skeletal muscle mass, insulin sensitivity, and beta-cell function in the development of type 2 diabetes: a 16-year prospective cohort study. J Endocr Soc. 2024;8(Suppl 1), ENDO 2024 conference abstract.
- Exercise-induced myokines in metabolic regulation: mechanisms, mimetics, and translational potential. Arch Pharm Res. 2026. doi:10.1007/s12272-026-01624-x. link.springer.com
- Cruz-Jentoft AJ, et al. Sarcopenia: revised European consensus on definition and diagnosis (EWGSOP2). Age Ageing. 2019;48(1):16 to 31. pmc.ncbi.nlm.nih.gov/articles/PMC6322506
- Petermann-Rocha F, et al. Global prevalence of sarcopenia and severe sarcopenia: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2022;13:86 to 99. pubmed.ncbi.nlm.nih.gov/34816624
- Goodpaster BH, et al. The loss of skeletal muscle strength, mass, and quality in older adults: the Health, Aging and Body Composition Study. J Gerontol A Biol Sci Med Sci. 2006;61:1059 to 1064.
- Newman AB, et al. Strength, but not muscle mass, is associated with mortality in the Health, Aging and Body Composition Study cohort. J Gerontol A Biol Sci Med Sci. 2006;61(1):72 to 77. pubmed.ncbi.nlm.nih.gov/16456196
- Leong DP, et al. Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study. Lancet. 2015;386(9990):266 to 273. pubmed.ncbi.nlm.nih.gov/25982160
- Zhao et al. Long-term impact of sarcopenia on functional decline and mortality in community-dwelling older adults: a systematic review and meta-analysis. Front Nutr. 2026;12:1652386. pmc.ncbi.nlm.nih.gov/articles/PMC12823505
- World Health Organization. WHO Guidelines on Physical Activity and Sedentary Behaviour. Geneva, 2020. who.int/publications/i/item/9789240015128
- Momma H, Kawakami R, Honda T, Sawada SS. Muscle-strengthening activities are associated with lower risk and mortality in major non-communicable diseases: a systematic review and meta-analysis of cohort studies. Br J Sports Med. 2022;56:755 to 763. doi:10.1136/bjsports-2021-105061. researchgate.net
- Tan Z, et al. Optimizing prescription of resistance training in older adults with sarcopenia: a systematic review and meta-analysis. Eur Rev Aging Phys Act. 2026;23:8. doi:10.1186/s11556-025-00399-2. link.springer.com
- Benefits of resistance training in frailty and sarcopenia: a systematic review and meta-analysis. J Clin Med. 2021;10:1630. mdpi.com/2077-0383/10/8/1630
- Fiatarone MA, et al. Exercise training and nutritional supplementation for physical frailty in very elderly people. N Engl J Med. 1994;330:1769 to 1775.
- Morton RW, et al. A systematic review, meta-analysis and meta-regression of the effect of protein supplementation on resistance training-induced gains in muscle mass and strength in healthy adults. Br J Sports Med. 2018;52(6):376 to 384. doi:10.1136/bjsports-2017-097608. ovid.com
- Endocrine Society. Statement on Testosterone Replacement Therapy. 16 July 2026, updated 9 September 2026. endocrine.org
- European Menopause and Andropause Society. Testosterone replacement therapy in older men: position statement. Maturitas. 2023;178:107854. emas-online.org (PDF)
- Additional sources cited in the myokine explorer: Pedersen BK, Febbraio MA. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol Rev. 2008;88:1379 to 1406 (PMC5538267); McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-β superfamily member. Nature. 1997;387:83 to 90; Boström P, et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481:463 to 468; Timmons JA, et al. Is irisin a human exercise gene? Nature. 2012;488:E9, E10 (nature.com/articles/nature11364); Kanzleiter T, et al. The myokine decorin is regulated by contraction and involved in muscle hypertrophy. Biochem Biophys Res Commun. 2014;450(2):1089 to 1094 (pubmed.ncbi.nlm.nih.gov/24996176); Erickson KI, et al. Exercise training increases size of hippocampus and improves memory. Proc Natl Acad Sci USA. 2011;108:3017 to 3022 (hippocampal finding as reported in secondary summaries).
Educational content only; not medical advice and not a substitute for an individual clinical assessment. Protein and training targets are population guidelines from the cited sources. Adjust them with your clinician if you have kidney disease, joint limitations, or other conditions. Figures are drawn from the cited studies as researched on 15 November 2026; items flagged in the text as conference abstracts, news summaries, or secondary reports had not been verified against their primary papers at that date.


